Ontology highlight
ABSTRACT: Objectives
To evaluate the safety, pharmacokinetics, and preliminary efficacy of NT-814, a dual neurokinin 1,3 antagonist, in postmenopausal women with vasomotor symptoms (hot flashes).Methods
We completed a double-blind, randomized, placebo-controlled trial in three US clinical research units in 76 postmenopausal women with moderate/severe hot flashes. Participants were randomized to 14 days of once-daily NT-814 or placebo within each of four sequential dose cohorts; 50, 100, 150, and 300 mg. Participants completed diaries of hot flash frequency and severity and waking due to night sweats before (baseline) and during treatment.Results
All prespecified efficacy parameters (24-h hot flash frequency and severity, frequency of waking due to night sweats) decreased in a
SUBMITTER: Trower M
PROVIDER: S-EPMC7188053 | biostudies-literature | 2020 May
REPOSITORIES: biostudies-literature